Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.53 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | NPR1 | P16066 | 1/20 | 0.34 |
| ▸ | NPR3 | P17342 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 2/20 | 0.32 |
| ▸ | CTSG | P08311 | 1/20 | 0.30 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
| ▸ | KLK7 | P49862 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8236190 | 0.90 | CTSL (0.66) | CTSLDRD1PTGS1PDE4AALB | |
| SCHEMBL8244573 | 0.87 | CTSL (0.64) | CTSLDRD1PTGS1PDE4AALB | |
| SCHEMBL8227371 | 0.87 | CTSL (0.64) | CTSLDRD1PTGS1PDE4AALB | |
| SCHEMBL8227193 | 0.85 | CTSL (0.58) | CTSLDRD1PTGS1PDE4AALB | |
| SCHEMBL8424783 | 0.85 | CTSL (0.58) | CTSLDRD1PTGS1PDE4AALB | |
| SCHEMBL8242592 | 0.85 | CTSL (0.58) | CTSLDRD1PTGS1PDE4AALB | |
| SCHEMBL8242455 | 0.84 | CTSL (0.60) | CTSLDRD1PTGS1PDE4AALB | |
| SCHEMBL14215178 | 0.84 | CTSL (0.57) | CTSLDRD1PTGS1PDE4AALB | |
| SCHEMBL8227168 | 0.84 | CTSL (0.74) | CTSLDRD1PTGS1PDE4ANPR1 | |
| SCHEMBL8244946 | 0.83 | CTSL (0.59) | CTSLDRD1PTGS1PDE4AALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194714-A1 | Novel depsipeptides and process for preparing same | CUBIST PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194714-A1 | Novel depsipeptides and process for preparing same | VIP, DNPEP, PREP | CTSL 124/4885DRD1 2758/4885PTGS1 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.